Novartis unit Sandoz has received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim).

Ziextenzo is intended to cut down the duration of neutropenia and incidence of febrile neutropenia in adult patients undergoing cytotoxic (anti-cancer) chemotherapy for malignancy, with the exception being chronic myeloid leukemia and myelodysplastic syndromes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sandoz global head of biopharmaceuticals Stefan Hendriks said: “Despite advancements in cancer treatment, febrile neutropenia remains one of the most significant complications of chemotherapy and is a major cause of morbidity.

“With the approval of Ziextenzo, a long-acting version of oncology supportive medicine filgrastim, we look forward to providing a treatment option that delivers the possibility of further reducing both the personal and financial burden of cancer.”

“An active substance in Ziextenzo called pegfilgrastim is a long-acting form of filgrastim, which boosts white blood cell production.”

This approval comes on the basis of analytical, preclinical and clinical data. These studies showed that Ziextenzo matched the reference medicine in terms of safety, efficacy and quality aspects.

An active substance in Ziextenzo called pegfilgrastim is a long-acting form of filgrastim, which boosts white blood cell production.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Filgrastim is very similar to natural protein granulocyte-colony stimulating factor, also called G-CSF, produced by the body.

It may be used to cut down the duration of neutropenia, which is low white blood cell count, and the occurrence of febrile neutropenia, in which patients suffer from low white blood cell count along with fever. Febrile neutropenia is caused due to cytotoxic chemotherapy.

Sandoz has eight approved biosimilars worldwide, including five in just last 18 months.